These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29878901)

  • 1. DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy.
    Bernier C; Soliman A; Gravel M; Dankner M; Savage P; Petrecca K; Park M; Siegel PM; Shore GC; Roulston A
    Anticancer Drugs; 2018 Sep; 29(8):774-785. PubMed ID: 29878901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
    Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
    Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
    Reguera-Nuñez E; Xu P; Chow A; Man S; Hilberg F; Kerbel RS
    J Exp Clin Cancer Res; 2019 Jan; 38(1):16. PubMed ID: 30635009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer.
    Teo ZL; Versaci S; Dushyanthen S; Caramia F; Savas P; Mintoff CP; Zethoven M; Virassamy B; Luen SJ; McArthur GA; Phillips WA; Darcy PK; Loi S
    Cancer Res; 2017 Nov; 77(22):6340-6352. PubMed ID: 28947417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.
    Brockwell NK; Owen KL; Zanker D; Spurling A; Rautela J; Duivenvoorden HM; Baschuk N; Caramia F; Loi S; Darcy PK; Lim E; Parker BS
    Cancer Immunol Res; 2017 Oct; 5(10):871-884. PubMed ID: 28848054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.
    Bush TL; Payton M; Heller S; Chung G; Hanestad K; Rottman JB; Loberg R; Friberg G; Kendall RL; Saffran D; Radinsky R
    Mol Cancer Ther; 2013 Nov; 12(11):2356-66. PubMed ID: 23990115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.
    Liu L; Wang Y; Miao L; Liu Q; Musetti S; Li J; Huang L
    Mol Ther; 2018 Jan; 26(1):45-55. PubMed ID: 29258739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
    Proia DA; Zhang C; Sequeira M; Jimenez JP; He S; Spector N; Shapiro GI; Tolaney S; Nagai M; Acquaviva J; Smith DL; Sang J; Bates RC; El-Hariry I
    Clin Cancer Res; 2014 Jan; 20(2):413-24. PubMed ID: 24173541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models.
    Schönfeld K; Herbener P; Zuber C; Häder T; Bernöster K; Uherek C; Schüttrumpf J
    Pharm Res; 2018 Apr; 35(6):118. PubMed ID: 29666962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo.
    Hsieh YL; Tu HJ; Pan SL; Liou JP; Yang CR
    Biochim Biophys Acta Mol Cell Res; 2019 Jun; 1866(6):992-1003. PubMed ID: 30867138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer.
    Sceneay J; Goreczny GJ; Wilson K; Morrow S; DeCristo MJ; Ubellacker JM; Qin Y; Laszewski T; Stover DG; Barrera V; Hutchinson JN; Freedman RA; Mittendorf EA; McAllister SS
    Cancer Discov; 2019 Sep; 9(9):1208-1227. PubMed ID: 31217296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer.
    Dávila-González D; Choi DS; Rosato RR; Granados-Principal SM; Kuhn JG; Li WF; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
    Clin Cancer Res; 2018 Mar; 24(5):1152-1162. PubMed ID: 29301832
    [No Abstract]   [Full Text] [Related]  

  • 14. An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance.
    Deng S; Krutilina RI; Wang Q; Lin Z; Parke DN; Playa HC; Chen H; Miller DD; Seagroves TN; Li W
    Mol Cancer Ther; 2020 Feb; 19(2):348-363. PubMed ID: 31645441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
    Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
    Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.
    Xiang J; Hurchla MA; Fontana F; Su X; Amend SR; Esser AK; Douglas GJ; Mudalagiriyappa C; Luker KE; Pluard T; Ademuyiwa FO; Romagnoli B; Tuffin G; Chevalier E; Luker GD; Bauer M; Zimmermann J; Aft RL; Dembowsky K; Weilbaecher KN
    Mol Cancer Ther; 2015 Nov; 14(11):2473-85. PubMed ID: 26269605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
    Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
    Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.
    Bello E; Taraboletti G; Colella G; Zucchetti M; Forestieri D; Licandro SA; Berndt A; Richter P; D'Incalci M; Cavalletti E; Giavazzi R; Camboni G; Damia G
    Mol Cancer Ther; 2013 Feb; 12(2):131-40. PubMed ID: 23270924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models.
    Revia S; Neumann F; Jabs J; Orio F; Sirrenberg C; Zimmermann A; Amendt C; Albers J
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2.
    Pandiella A; Morís F; Ocaña A; Núñez LE; Montero JC
    Oncotarget; 2015 Oct; 6(32):32856-67. PubMed ID: 26439989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.